Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 665 of 6351
-
Youth-Led arts program aims to curb community violence
Prevention Recruiting nowThis behavioral intervention study aims to evaluate the effectiveness of Youth Empowered Advocating for Health (YEAH) on youth prosocial behavior and aggressive behavior and assess racial identity and future orientation as mediators of prevention effects.
Sponsor: Emory University • Aim: Prevention
Last updated Sep 02, 2026 00:00 UTC
-
Fertility shield: new trial tests triptorelin to save ovaries during chemo
Disease control Recruiting nowThis phase III trial compares the effect of giving triptorelin vs no triptorelin in preventing ovarian damage in adolescents and young adults (AYAs) with cancer receiving chemotherapy with alkylating agents. Alkylating agents are part of standard chemotherapy, but may cause damag…
Phase 3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New vaccine combo could simplify infant shots
Vaccine OngoingThis study is a Phase 3, randomized, modified double-blind study which aims to measure whether the investigational pneumococcal conjugate vaccine PCV21 is safe and can help the body to develop germ-fighting agents called "antibodies" (immunogenicity) when it is given after 1 dose…
Phase 3 • Sponsor: Sanofi • Aim: Vaccine
Last updated Jun 27, 2026 09:04 UTC
-
New study aims to close diabetes care gap with smart insulin pumps
Disease control Recruiting nowMinoritized individuals with type 1 diabetes (T1D) have approximately 2% higher average A1c levels and twice the rate of hospitalizations, complications, and mortality as their white counterparts. However, the efficacy trials establishing the benefits of hybrid closed loop (HCL) …
Sponsor: Boston Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise in Hard-to-Treat eye cancer
Disease control OngoingThe goal of this clinical trial is to learn how roginolisib works in comparison to standard treatment in adult patients with uveal/ocular melanoma. The main questions it aims to answer are: Does roginolisib extend overall survival compared to standard treatment? How does dosing …
Phase 2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Could a new drug help tiny babies feed faster?
Disease control Recruiting nowThe study will evaluate the effect of ELGN-2112 on intestinal malabsorption in preterm infants.
Phase 3 • Sponsor: Elgan Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Brain zap plus therapy may help teens tame tics
Disease control Recruiting nowChronic tics are a disabling neuropsychiatric symptom associated with multiple child-onset mental disorders. Chronic tics affect 1-3% of youth 1 and are associated with impaired functioning, emotional and behavioral problems, physical pain, diminished quality of life, peer victim…
Phase 2 • Sponsor: University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
Can sealing the wound after polyp removal cut bleeding risk?
Disease control Recruiting nowThe goal of this clinical trial is to compare adverse even rates after EMR for large (≥20mm) flat colorectal polyps (so-called laterally spreading lesions, LSLs) when performing complete or no defect closure. It will also evaluate lesion recurrence after EMR for large colorectal …
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New hope for Tough-to-Treat prostate cancer: experimental drug AAA817 faces off against standard care
Disease control Recruiting nowThis is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after \[177Lu\]Lu-PSMA targeted therapy. Treatment of interest: t…
Phase 2/3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New injection aims to stabilize platelets in chronic ITP patients
Disease control Recruiting nowPrimary immune thrombocytopenia (ITP) is a condition where the immune system mistakenly destroys platelets, which are cells that help stop bleeding. This leads to a low number of platelets, making it easier to bruise or bleed. The main aim of this study is to learn whether mezagi…
Phase 3 • Sponsor: Takeda • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can gentler therapy beat harsh chemo for tough leukemia?
Disease control Recruiting nowThis is a multicenter, randomized, open-label, pragmatic low intervention clinical trial comparing high intensity reinduction chemotherapy with low intensity therapies in 1st or 2nd relapse Acute Myeloid Leukemia. The study is funded by European Commission (HORIZON-MISS-2022-CANC…
Phase 3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for tough lung cancer: dual-drug attack shows promise
Disease control Recruiting nowResearchers are looking for new ways to treat people with extensive-stage small cell lung cancer (SCLC) that has relapsed or is refractory. Gocatamig is a new type of immunotherapy that uses a person's immune system to find and destroy cancer cells. Ifinatamab deruxtecan (also kn…
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 10, 2026 08:00 UTC
-
One-Time gene therapy could shield lungs in rare disease
Disease control Recruiting nowThis is a study of gene therapy to treat alpha 1-antitrypsin (AAT) deficiency. This study aims to treat AAT deficiency with a single administration of AAV8hAAT(AVL), a gene therapy that codes for an oxidation resistant form of the AAT protein, which if safe and if efficacious, wi…
Phase 1 • Sponsor: Weill Medical College of Cornell University • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Two-Drug punch before surgery shows promise against head and neck cancer
Disease control OngoingThe purpose of the study is to determine if cemiplimab in combination with cetuximab given before their surgery are beneficial and safe in participants with head and neck squamous cell carcinoma (HNSCC).
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New drug shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowResearchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: …
Phase 1/2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New combo therapy targets tough pancreatic cancer in 20-Patient trial
Disease control Recruiting nowA phase II study combining pembrolizumab with olaparib in metastatic pancreatic adenocarcinoma patients with high tumour mutation burden
Phase 2 • Sponsor: Cambridge University Hospitals NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for HIV-positive moms: counseling tackles depression and boosts care
Disease control Recruiting nowThe main objective of the proposed study is to evaluate the effectiveness of the Enhanced Friendship Bench intervention to improve perinatal depression, HIV care engagement, and infant health outcomes among pregnant women with HIV and depression in Malawi.
Sponsor: University of North Carolina, Chapel Hill • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug tarlatatamab shows promise in lung cancer trial
Disease control OngoingThe primary objective of this study is to describe the antitumor activity of tarlatamab in participants with small cell lung cancer (SCLC).
Phase 2 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Predictive model may personalize ICU feeding to cut intolerance
Disease control Recruiting nowProject Name: Improved Feeding Regimen for Critically Ill Patients (mNEED) Based on Feeding Intolerance Prediction Model Solution version number and version date: Version 5.0; 2024.12.16 Informed consent version number and version date: Version 1.0; 2023.10.19 Dear Patient, Rece…
Sponsor: The First Hospital of Jilin University • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Supercharged immune cells take on hard-to-treat melanoma in early trial
Disease control Recruiting nowTo find the highest tolerable dose and recommended dose of PRAME-TCR-NK cells that can be given to participants with recurrent and/or refractory melanoma. The safety and tolerability of PRAME-TCR-NK cells will also be studied.
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC